Management of a chronic skin disease in primary care: An analysis of early-career general practitioners' consultations involving psoriasis by Nawaz, S et al.
Dermatology Practical & Conceptual
Research | Dermatol Pract Concept 2021;11(3):e2021055 1
Management of a Chronic Skin Disease in 
Primary Care: An Analysis of Early-Career General 
Practitioners’ Consultations Involving Psoriasis 
Sameerah Nawaz1, Amanda Tapley 2, 3, Andrew R. Davey 2, 3 Mieke L. van Driel4, Alison Fielding 2,3, 
Elizabeth G. Holliday2, Jean Ball5, Irena Patsan2,3, Alyse Berrigan3, Simon Morgan1, Neil A. Spike6,7, 
Kristen FitzGerald8,9, Parker Magin2,3
1 GP Synergy, Regional Training Organisation, Liverpool, NSW, Australia 
2 The University of Newcastle, School of Medicine and Public Health, Callaghan, NSW, Australia
3 GP Synergy, Regional Training Organisation, NSW & ACT Research and Evaluation Unit, Mayfield West, NSW, Australia
4 The University of Queensland Faculty of Medicine, Primary Care Clinical Unit, Brisbane, QLD, Australia
5 Hunter Medical Research Institute, Clinical Research Design, IT and Statistical Support Unit (CReDITSS), New Lambton, NSW, Australia
6 Eastern Victoria GP Training, General Practice Training Organisation, Melbourne, Australia
7 The University of Melbourne, Department of General Practice, Melbourne, VIC, Australia
8 University of Tasmania, School of Medicine, Hobart, TAS, Australia
9 General Practice Training Tasmania (GPTT), Regional Training Organisation, Hobart, TAS, Australia
Key words: general practice, family practice, psoriasis, continuity of patient care, medical and graduate education, chronic disease
Citation: Nawaz S, Tapley A, Davey AR, van Driel ML, Fielding A, Holliday EG, Ball J, Patsan I, Berrigan A, Morgan S, Spike NA, 
FitzGerald K, Magin P. Management of a chronic skin disease in primary care: an analysis of early-career general practitioners’ 
consultations involving psoriasis Dermatol Pract Concept. 2021;11(3):e2021055. DOI: https://doi.org/10.5826/dpc.1103a55
Accepted: December 14, 2020; Published: May 20, 2021
Copyright: ©2021 Nawaz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors 
and source are credited.
Funding: The ReCEnT project was funded from 2010 to 2015 by the participating educational organisations: General Practice Training 
Valley to Coast, the Victorian Metropolitan Alliance, General Practice Training Tasmania, Adelaide to Outback GP Training Program, and 
Tropical Medical Training, all of which were funded by the Australian Government Department of Health. From 2016-2019, ReCEnT is 
funded by an Australian Government Department of Health commissioned research grant and supported by GP Synergy Regional Training 
Organisation. GP Synergy is funded by the Australian Government Department of Health.
Competing interests: The authors have no conflicts of interest to disclose.
Authorship: All authors have contributed significantly to this publication.
Corresponding author: Parker Magin, PhD, FRACGP, 20 McIntosh Dr, Mayfield West, 2304 NSW, Australia.  
Email: parker.magin@newcastle.edu.au
Background: The management of psoriasis by general practitioners (GPs) is vital, given its prevalence, 
chronicity, and associated physical and psychosocial co-morbidities. However, there is little informa-
tion on how GPs (including early-career GPs) manage psoriasis. 
Objectives: This study assessed the frequency with which Australian specialist GP vocational trainees 
(‘registrars’) provide psoriasis care and the associations of that clinical experience.
Methods: A cross-sectional analysis was done of data from the ReCEnT study, an ongoing multi-
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Introduction 
Psoriasis is an autoimmune and autoinflammatory condition 
resulting in chronic inflammation of the skin and, typically, 
a prolonged clinical course. There are different phenotypes 
associated with varied genetics, immune pathophysiology 
and symptoms [1]. The most common type, chronic plaque 
psoriasis, comprises 90% of cases [2]. Other types of psoriasis 
include guttate psoriasis, generalised pustular psoriasis, pal-
moplantar psoriasis and erythrodermic psoriasis [3]. Psoriasis 
can also be classified into two types according to age at onset. 
Type I psoriasis is the more common type, comprising 75% of 
all cases, and is associated with early onset (before age 40) and 
more severe disease (HLA-Cw*0602 positive.) Type II psori-
asis is HLA-Cw*0602 negative, and occurs later in life [4].
There is a wide variation in the prevalence of psoriasis 
among different populations. Variations in prevalence may be 
attributable to study design (eg population-based versus hospi-
tal based, or self-reported versus clinician-diagnosed) or to geo-
graphic and environmental factors [5]. It is clear that Australia 
has a particularly high prevalence of psoriasis [6]. Psoriasis in 
Australian Aboriginal people, however, is rare or absent [7]. 
The burden of psoriasis on individuals can include sig-
nificant physical, social and psychological impacts [8,9]. 
Psoriasis is associated with lifestyle factors including obesity, 
smoking and alcohol use [10]. Independent of these risk 
factors, psoriasis is associated with multiple medical comor-
bidities including psoriatic arthritis (30%), inflammatory 
bowel disease, metabolic syndrome, non-alcoholic fatty liver 
disease, cardiovascular disease, myocardial infarction, dia-
betes, chronic renal disease and stroke [11-14]. Psychiatric 
and psychosocial comorbidities and impairment of quality 
of life are common and problematic [9,15,16]. Additionally, 
treatments for psoriasis can have adverse effects involving 
multiple systems [8]. Thus, given the prevalence, chronicity, 
and physical and psychosocial comorbidities of psoriasis, it is 
vital that general practitioners (GPs) are continually engaged 
in – and have expertise in – the management of psoriasis. 
Australian GPs (family physicians) encounter psoriasis 
with a frequency of approximately 0.2 in every 100 patient 
visits [17]. Patients’ experiences of GP consultations for 
psoriasis may often be negative, with many finding that GPs 
have limited knowledge and, more importantly, limited appre-
ciation of its impact on patients’ lives [18]. 
Registrars are early-career GPs practising within a 
national specialist general practice training program. They 
are establishing what may be long-lasting practice patterns 
in a clinical context of having been underprepared for man-
aging skin disease by their undergraduate and junior doctor 
experiences [19-21]. An understanding of consultation and 
management patterns, as with skin disease in general, can 
lead to a better understanding and improvement of psoriasis 
management in the community setting [22].
In this study, we aimed to establish the frequency and 
associations of psoriasis consultations in registrars’ clinical 
experience. In view of the chronicity of psoriasis, we were 
particularly interested in the associations of factors related 
to the continuity of care.
Materials and Methods
This was a cross-sectional analysis of data from the 
 Registrar Clinical Encounters in Training (ReCEnT) study.
ReCEnT
ReCEnT is an ongoing multi-site cohort study of Aus-
tralian GP registrars. Participants are registrars in the 3 
compulsory general-practice-based training terms of Aus-
tralian GP vocational training. Registrars practice within an 
apprenticeship-like training model [23], but with considerable 
site cohort study of Australian GP registrars’ experiences during vocational training. In ReCEnT, 60 
consecutive consultations are recorded 3 times (6-monthly) during each registrar’s training. The out-
come factor for this analysis was a problem/diagnosis being psoriasis, and independent variables were 
related to registrar, patient, practice and consultation factors. This study analysed 17 rounds of data 
collection (2010-2017) using univariate and multivariable regression. 
Results: Data from 1,741 registrars regarding 241,888 consultations and 377,980 problems/diagno-
ses were analysed. Psoriasis comprised 0.15% (n=550) of all problems/diagnoses (95% CI, 0.13-0.16). 
Significant patient multivariable associations of a problem/diagnosis being psoriasis included age, gen-
der, being new to a practice or a registrar, and psoriasis being an existing problem rather than a new 
diagnosis. Significant registrar associations included seeking in-consultation information/assistance, 
not scheduling a follow-up appointment, prescribing medication, and generating learning goals. 
Conclusions: Australian registrars have modest training exposure to psoriasis and may find psori-
asis management challenging. Furthermore, continuity of care (essential for optimal chronic disease 
management) was modest. The findings have implications for GPs’ approaches to the management of 
psoriasis more widely as well for general practice education and training policies.
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clinical autonomy (whereby they can request assistance from 
their experienced GP supervisor, if required). From 2010 to 
2015, 5 of Australia’s 17 Regional Training Providers (RTPs) 
participated and, since 2016, 3 of Australia’s 9 Regional 
Training Organisations (RTOs) have participated (in 2016 
there was a major restructuring of Australian GP training). 
RTOs and RTPs are geographically defined, not-for-profit 
educational organisations. Hereafter, RTOs, RTPs and RTO 
subregions are referred to as ‘regions’. At the time of this 
analysis, individual regions had contributed from 3 to 17 
rounds of data collection. 
The methodology has been described elsewhere [24]. 
Briefly, registrars undertake data collection once per 6-month 
training term as an integral component of their educational 
program [25]. The data are used to compose detailed writ-
ten feedback reports for registrar reflection on their clinical 
practice and educational and training needs. Registrars may 
provide written informed consent for their de-identified data 
to also be used for research purposes. Initial data collection 
involves registrar demographic, educational, and work expe-
rience, plus characteristics of the practice in which they are 
currently working. 
Approximately mid-way through the training term, reg-
istrars record the details of 60 consecutive patient consulta-
tions on a paper-based Case Report Form. As data collection 
is designed to reflect a ‘normal’ week of general practice, 
consultations in a specialised clinic, eg vaccination clinic, are 
excluded. Only office-based consultations (not home visits or 
nursing home visits) are recorded.
Outcome Factor
The outcome factor in this study was a problem/diagnosis 
being ‘psoriasis’. ‘Psoriasis’ was defined as the ICPC-2 code 
S91 001 (Psoriasis). In ReCEnT, problems/diagnoses are 
coded according to the International Classification of Primary 
Care, second edition classification system (ICPC-2 plus) [26]. 
Independent Variables 
Independent variables listed in Table 2 related to registrar, 
patient, practice, and consultation (including in-consultation 
educational factors). Each practice’s postal code was used to 
define the degree of rurality, according to the Australian Stan-
dard Geographical Classification-Remoteness Area (ASGC-RA) 
classification [27] and the location’s Socioeconomic Index for 
Area (SEIFA) Relative Index of Disadvantage [28]. 
Statistical Analysis
Analysis was performed on 17 rounds of data collected 
from 2010 to 2017. Analysis was at the level of individual 
problem/diagnosis. The proportions of registrars’ problems/
diagnoses that were psoriasis and of consultations involving a 
psoriasis problem/diagnosis were calculated, with 95% confi-
dence intervals, adjusted for clustering within registrars. To test 
associations of a problem/diagnosis being psoriasis, simple and 
multiple logistic regression were used within the generalised 
estimating equations (GEE) framework to account for clus-
tering of patients within registrars. (This is the lowest level of 
clustering in the study design: previous analyses of the ReCEnT 
data set have demonstrated that also adjusting for clustering 
at practice level is non-contributory.) All variables with a P 
value less than .20 in the univariate analysis were included 
in the multiple regression model. Covariates with P >.2 in the 
resulting multivariable model were tested for removal. If the 
covariate’s removal did not substantively change the model, 
the covariate was removed from the final model.
The outcome proportion for psoriasis was very low 
(0.15%), which can cause problems of complete or qua-
si-complete separation of data. This means that the outcome 
variable separates a predictor variable or a combination of 
predictor variables completely. To check for the impact of 
data separation, logistic regression coefficients were estimated 
using Firth’s penalised likelihood in a sensitivity analysis. 
Coefficients differed negligibly in the sensitivity analysis, and 
thus results from standard logistic regression were reported. 
Results from the logistic regression were reported as odds 
ratios (OR) with 95% confidence intervals. 
In order to examine 3 separate issues within our overall 
research question, 3 models were built, each with ‘psoriasis 
being the problem/diagnosis’ as the dependent variable:
a) To examine the question of associations of a problem/
diagnosis being psoriasis, patient, practice, and registrar 
independent variables were entered in an initial regres-
sion model.
b) To examine the question of in-consultation differences 
of a psoriasis problem/diagnosis problem compared with 
other problems/diagnoses, the above variables were entered 
in a model along with the following additional variables: 
consultation duration, information/assistance accessed by 
the registrar, number of problems/diagnoses dealt with in 
the consultation, and consultation duration.
c) To examine the question of whether actions arising from 
managing psoriasis differ from those arising from other 
problems/diagnoses, all variables entered in the previous 
2 models were entered in a new model along with the fol-
lowing additional variables: learning goals generated by 
the registrar, follow-up organised, specialist referrals made, 
and pathology tests and imaging exams ordered.
The rationale for the building of the 3 models was that 
whether a patient presents with psoriasis (our first ques-
tion) will plausibly be influenced by patient, registrar, and 
practice factors, but evaluation of this question may be 
biased by inclusion in the model of factors operating once 
the consultation is progressing. Similarly, evaluation of the 
content of the consultation (our second question), may be 
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biased by the inclusion in the model of actions arising from 
the consultation. 
The frequencies with which medicines were prescribed 
for psoriasis, and with which referrals were made, were 
calculated. The frequency with which sources of in-con-
sultation information or assistance were sought was also 
calculated. 
Statistical analyses were programmed using STATA 14.0 
and SAS v9.4. P values <.05 were considered statistically 
significant.
Ethics Approval
The ReCEnT project has approval from the University 
of Newcastle Human Research Ethics Committee (Reference 
H-2009-0323).
Results
The study analysed data from a total of 1,741 registrars 
(response rate, 96.0%). The demographics of participating 
registrars are presented in Table 1. The registrars provided 
data on 241,888 consultations and 377,980 problems/diag-
noses.  Of all problems/diagnoses, 550 (0.15% [95% CI, 
0.13-0.16]) were a psoriasis problem/diagnosis. This equates 
to 0.22% of all consultations (95% CI, 0.20-0.24). 
Associations of Psoriasis Problems/Diagnoses 
Managed by Registrars
Table 2 presents the characteristics associated with a 
problem/diagnosis being psoriasis in the 1,741 registrars’ 
practices. 
Table 3 presents the results of simple and multiple logis-
tic regression analyses. Significant patient associations on 
multivariable analysis of the problem/diagnosis being pso-
riasis were age group 15-34 (compared to younger or older 
patients), male gender (OR = 0.7 for female gender), the 
patient being new to the practice (OR = 2.6 compared to an 
existing patient of the practice), the patient being new to the 
registrar (OR = 2.1 compared to an existing patient of the 
practice), and the problem being an existing one (OR = 0.1 
for a new problem). The significant registrar association was 
training term 3 (OR = 1.3 compared to term 1). The signifi-
cant multivariable consultation association of the problem/
diagnosis being psoriasis was seeking in-consultation infor-
mation or assistance (OR = 2.4).
Table 1. Participating trainee, trainee-term and practice characteristics
Variable Class n (%) or Mean (SD)
Registrar variables (n=1741)
Registrar Gender Female 1,116 (64.1)
Pathway registrar enrolled in
(General or Rural)
Rural 446 (25.8)
International Medical Graduate or Qualified as a 
doctor in Australia
International Graduate 302 (17.5)
Registrar-term or practice-term variables (n=4072)
Registrar Training Term 
Term 1 1,613 (39.6)
Term 2 1,471 (36.1)
Term 3 988 (24.3)
Registrar age (years) Mean (SD) 32.4 (6.1)
Registrar works full time Yes 3079 (77.7)
Registrar worked at the current practice previously Yes 996 (24.8)
Does the practice routinely bulk bill1 all patients Yes 898 (22.4)
Number of GPs working at the practice 1-5 1,430 (36.2)
6-9 2,526 (63.9)
Rurality of practice
Major City 2,443 (60.2)
Inner Regional 1,021 (25.2)
Outer regional, remote or very 
remote
594 (14.6)
SEIFA2 Index of practice Mean (SD) 5.5 (2.8)
1 Bulk bill, to charge the entire costs of an episode of patient care to the Australian national health care system.
2 SEIFA = Socioeconomic Index for Area Relative Index of Disadvantage.
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Total 377,430 (100) 550 (100) -
Patient Variables
Age group (years) 0-14 52,353 (14) 19 (4) <.001
15-34 98,406 (26) 149 (28)
35-64 147,691 (40) 278 (51)
≥65 73,227 (20) 95 (18)
Gender Male 138,926 (38) 251 (47) <.001
Female 229,392 (62) 288 (53)
Aboriginal Torres Strait Islander 
status
No 348,082 (98) 501 (98) .32
Yes 5,657 (2) 11 (2)
Non-English-speaking background No 328,363 (92) 480 (94) .23
Yes 28,129 (8) 33 (6)
Patient/practice status Existing patient 158,290 (43) 180 (34) <.001
New to registrar 184,591 (50) 312 (58)
New to practice 25,953 (7) 43 (8)
Registrar Variables
Gender Male 131,335 (35) 199 (36) .54
Female 246,095 (65) 351 (64)
Works full time No 84,158 (23) 117 (22) .53
Yes 283,552 (77) 422 (78)
Term Term 1 152,328 (40) 223 (41) .14
Term 2 134,357 (36) 177 (32)
Term 3 90,745 (24) 150 (27)
Worked at practice previously No 279,145 (75) 416 (76) .42
Yes 93,406 (25) 128 (24)
Qualified as doctor in Australia No 63,796 (17) 75 (14) .058
Yes 311,330 (83) 470 (86)
Age (years) Mean (SD) 32 (6) 32 (6) .76
Practice Variables
Practice size Small 134,317 (37) 192 (35) .58
Large 232,596 (63) 349 (65)
Routine bulk billing2 No 289,580 (78) 418 (77) .68
Yes 83,118 (22) 125 (23)
Rurality Major city 225,666 (60) 337 (62) .48
Inner regions 94,719 (25) 125 (23)
Outer regions or remote 55,786 (15) 85 (16)
Sub-region 1 100,799 (27) 146 (27) .89
2 36,149 (10) 46 (8)
3 49,566 (13) 74 (13)
4 151,255 (40) 227 (41)
5 10,400 (3) 12 (2)
6 29,261 (8) 45 (8)
SEIFA (decile) Mean (SD) 5 (3) 6 (3) .28
Table 2. Continues
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Significant multivariable associations with factors arising 
from the registrar’s management of the problem/diagnosis 
included follow-up being less likely (OR = 0.7 for organising 
follow-up), medication being prescribed (OR = 3.8),and 
learning goals being generated (OR = 2.8).
Medication was prescribed for 435 (79%) of psoriasis 
problems/diagnoses. The most common medicines prescribed 
for psoriasis were betamethasone (31% of all prescriptions 
for psoriasis), mometasone (21%) and calcipotriol and com-
binations (20.0%).  See Table 4 for the list of most commonly 
prescribed medications.
Only 180 patients with psoriasis problems/diagnoses (34%) 
had seen the registrar previously (for any reason), and for only 
199 psoriasis problems/diagnoses (36%) was follow-up organ-
ised. In 89% of instances, this was with the registrar personally. 
When seen for psoriasis, 13% of patients were referred to a 
dermatologist, with 9% of new diagnoses being referred and 
15% of previously diagnosed patients being referred.  
In-consultation information or assistance was accessed 
for 29% of psoriasis problems/diagnoses. The sources of 
in-consultation assistance or information used were electronic 
sources (64%), the registrar’s supervisor (33% of instances), 
hard-copy sources (6%), and specialists (4%).
Discussion
Frequency of Psoriasis Problems/Diagnoses 
Encountered 
We found that 0.22% of registrar consultations involved 
a psoriasis diagnosis/problem. While this is comparable to 
the frequency with which established GPs encounter psoriasis 
[17], this equates to approximately once every 8 weeks, or 
approximately 10 times during registrars’ 3 core general prac-
tice training terms. This relative low frequency of registrars 
managing psoriasis (together with a lack of undergraduate 
and hospital doctor experience of skin disease) [19] suggests 
these early-career GPs may have unmet learning needs related 
to psoriasis. This is consistent with the association we found 
with high levels of seeking in-consultation information or 
assistance and generation of learning goals in relation to 






New problem seen No 152,857 (44) 417 (84) <.001
Yes 192,886 (56) 80 (16)
Sought help from any source No 315,534 (84) 391 (71) <.001
Yes 61,896 (16) 159 (29)
Consultation duration (minutes) Mean (SD) 19 (10) 19 (10) .47
Number of problems  dealt with in 
the consultation
Mean (SD) 2 (1) 2 (1) .002
Consultation Outcome Variables
Imaging exam ordered No 348,644 (92) 546 (99.3) <.001
Yes 28,786 (8) 4 (0.7)
Pathology exam ordered No 308,712 (82) 506 (92) <.001
Yes 68,718 (18) 44 (8)
Learning goals generated No 298,600 (83) 338 (65) <.001
Yes 61,465 (17) 179 (35)
Follow-up ordered No 211,640 (56) 351 (64) <.001
Yes 165,790 (44) 199 (36)
Referral ordered No 331,078 (88) 470 (85) .11
Yes 46,352 (12) 80 (15)
Medication prescribed No 211,612 (56) 115 (21) <.001
Yes 165,818 (44) 435 (79)
SEIFA = Socioeconomic Index for Area Relative Index of Disadvantage.
1 Values are n (%) unless otherwise indicated. Percentages are out of the total number of problems/diagnoses.
2 Bulk bill, to charge the entire costs of an episode of patient care to the Australian national health care system.
Table2. Characteristics Associated With a Problem/Diagnosis in Registrars’ Practice Being Psoriasis 
(continued)
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OR (95% CI) P OR (95% CI) P
Patient, Registrar and Practice Variables
Patient Age group 
(Referent: 15-34 years)
0-14 0.2 (0.2, 0.4) <.001 0.3 (0.2, 0.5) <.001
35-64 1.2 (1.0, 1.5) .041 1.0 (0.8, 1.3) .82
≥65 0.9 (0.7, 1.1) .24 0.7 (0.5, 0.9) .004
Patient Gender Female 0.7 (0.6, 0.8) <.001 0.7 (0.6, 0.8) <.001
Patient/practice status 
(Referent: existing patient)
New to practice 1.5 (1.1, 2.0) .023 2.6 (1.8, 3.7) <.001
New to registrar 1.5 (1.2, 1.8) <.001 2.1 (1.7, 2.5) <.001
Term (Referent: term 1) Term 2 0.9 (0.7, 1.1) .31 1.0 (0.8, 1.2) .75
Term 3 1.1 (0.9, 1.4) .27 1.3 (1.0, 1.6) .045
New problem seen Yes 0.2 (0.1, 0.2) <.001 0.1 (0.1, 0.2) <.001
Consultation Variables (adjusted for above variables) 
Sought help from any 
source
Yes 2.1 (1.7, 2.5) <.0001 2.4 (2.0, 3.0) <.001
Consultation Outcome Variables (adjusted for above variables) 
Imaging ordered Yes 0.1 (0.0, 0.2) <.001 0.1 (0.0, 0.4) <.001
Follow-up ordered Yes 0.7 (0.6, 0.9) <.001 0.7 (0.6, 0.8) <.001
Learning goals generated Yes 2.6 (2.2, 3.1) <.001 2.8 (2.1, 3.5) <.001
Pathology ordered Yes 0.4 (0.3, 0.5) <.001 0.4 (0.3, 0.6) <.001
Medication prescribed Yes 4.8 (3.9, 6.0) <.001 3.8 (3.0, 4.8) <.001






New Prescriptions, n (%)
Betamethasone 193 31.4 35.8
Mometasone 129 21.0 35.7
Calcipotriol and combinations 123 20.0 33.3
Methylprednisolone aceponate 35 5.7 80.0
Hydrocortisone 27 4.4 48.1
Methotrexate 13 2.1 7.7
Salicylic acid 13 2.1 69.2
Triamcinolone 12 2.0 41.7
Methylprednisolone 11 1.8 63.6
Clobetasol 6 1.0 33.3
Prednisolone 6 1.0 50.0
Dithranol and combinations 5 0.8 80.0
Patient Demographics Associated with Psoriasis
Our study showed that a patient being between the ages 
of 15 and 64 years was significantly associated with the 
problem/diagnosis being psoriasis (compared to younger or 
older patients). This is consistent with a previous study that 
found low rates of psoriasis in the paediatric population, 
with a peak starting at age 20 and declining after 60 [29]. 
Although previous studies have not found any consistent 
difference in prevalence by gender [6], our study showed a 
lower likelihood of registrars seeing psoriasis in females. A 
possible explanation is that psoriasis has been found to be 
more severe in males than in females, and our finding may 
reflect healthcare-seeking behaviours rather than community 
prevalence [30]. 
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Associations of a Psoriasis Problem/Diagnosis
The registrar being in term 3 (vs. term 1) of their training 
was significantly associated with a psoriasis problem/diag-
nosis. This, again, may reflect the paucity of dermatological 
experience and expertise of registrars entering general prac-
tice and increasing confidence and comfort in addressing 
psoriasis with more experience. 
A large number of medications was prescribed by regis-
trars for psoriasis. Most were (appropriately) topical steroids 
and vitamin D analogues. This (together with the strong 
association of psoriasis problems/diagnoses with in-consul-
tation assistance-seeking) suggests that, despite their lack of 
experience in this area, consultation with information sources 
and the GP registrars’ supervisor may facilitate appropriate 
treatment. 
Implications for the Management of Psoriasis as a 
Chronic Disease
This study found a strong association of consultations 
for psoriasis being for existing psoriasis. However, there 
were also strong associations of the patient being new to the 
practice, new to the registrar, and less follow-up appoint-
ments being organised. This suggests that these patients may 
have inconsistent provision of primary care for this problem. 
That is, there is low continuity of care (to some extent infor-
mational and management continuity but, especially, low 
interpersonal continuity) [31, 32]. This is contrary to findings 
of patients with chronic disease in general within this study 
population, where chronic disease is associated with greater 
continuity of care [33]. This is of considerable importance as 
psoriasis is a chronic disease with much associated morbidity 
(both psychosocial co-morbidity and high levels of co-morbid 
non-dermatological physical disease) [8, 9, 11, 15, 16]. One 
explanation for our finding is that psoriasis is being managed 
primarily by specialist dermatologists. Even if this were the 
case, shared care with a generalist is essential given the phys-
ical and psychosocial co-morbidities of psoriasis. Optimal 
generalist care, as for all chronic conditions, should include 
continuity of care. 
Another interpretation is that the patients lack continu-
ity of care with any clinician and that they do not receive 
coordinated care appropriate to their condition. This may 
be influenced by patients often not valuing GPs’ expertise 
in skin disease (including psoriasis). A feeling that GPs do 
not appreciate patients’ experience of skin disease has been 
reported [18]. Further associations in our study may support 
this interpretation. We found a strong association with the 
prescription of medicines and specialist referral. An inter-
pretation may be that many patients receive episodic care, 
often prompted by the need to renew psoriasis prescriptions 
and referrals,. They may be seeking a convenient prescriber 
performing a routine, discrete administrative task rather than 
a GP involved in ongoing, considered management of their 
chronic disease. Possible sequelae of such a situation are 
different providers delivering uncoordinated medicine regi-
mens that do not facilitate a logical progression of treatment 
based on response to past medications [34-36]. Furthermore, 
holistic care of patients is likely to be compromised with a 
lack of addressing physical and psychosocial morbidities. 
Lack of continuity of care will also compromise shared deci-
sion-making which has been advocated in the management of 
skin conditions in general [22] and in psoriasis management 
[37] in particular.
In this context, our finding that when registrars do orga-
nise a follow-up appointment for psoriasis, it is usually with 
themselves (rather than another GP in the practice) should 
be noted. It may suggest that they appreciate the importance 
of, and are attempting to facilitate, interpersonal continuity 
of care for psoriasis. 
Implications for Education and Training 
As we found evidence suggesting that registrars see little 
psoriasis in practice over the course of GP vocational training, 
targeted education and training in this area may be required. 
This could be addressed through structural changes within 
practice, appointment scheduling and policy regarding fol-
low-up, along with concurrent patient education regarding the 
needs for continuity of care for management of their psoriasis, 
including shared decision-making and self-management [22].
Conclusions
We have identified educational and organisational aspects 
of registrar psoriasis management that could be optimised 
with changes at a registrar, practice and patient level. Regis-
trars see relatively little psoriasis in practice during vocational 
training, and evidence was found to suggest that registrars 
are finding psoriasis care challenging. This suggests oppor-
tunity for more education and training in this area. We also 
found evidence that psoriasis (a chronic disease with frequent 
comorbidity), despite registrars’ attempts, did not show the 
same pattern of continuity of care that is usually seen in 
optimal chronic disease management.
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